Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

6.440 +0.320 (+5.23%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 25, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Tesla and Merck Give Investors Some Hope ↗

October 04, 2021

Friday’s rally appears to have lost its momentum over the weekend because stock futures are trading lower before Monday’s open. China’s troubled real estate...

Via Benzinga

54 Biggest Movers From Friday ↗

October 04, 2021

Check out these big penny stock gainers and losers Losers Spire Global, Inc.. (NYSE: SPIR) shares fell 43.3% to close at $7.10 on Friday. Spire Global, Inc....

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Biomerica Shares Spike Higher ↗

October 01, 2021

Toward the end of trading Friday, the Dow traded up 1.49% to 34,346.53 while the NASDAQ rose 0.75% to 14,556.92. The S&P also rose, gaining 1.18% to 4,358.52. The U.S. has the...

Via Benzinga

Topics Stocks

Unusual Options Activity Insight: Vir Biotechnology ↗

July 30, 2021

Shares of Vir Biotechnology (NASDAQ:VIR) saw some unusual ...

Via Benzinga

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗

July 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 01, 2021

Gainers Biomerica (NASDAQ:BMRA) stock moved upwards by 39.33% to $6.27 during Friday's regular session. As of 12:30 EST, Biomerica's stock is trading at a volume...

Via Benzinga

Merck Stock Surges Into Buy Zone As Covid Pill Reduces Risk Of Death, Hospitalization ↗

October 01, 2021

Merck said its Covid pill, molnupiravir, cut the risk of death and hospitalization by half.

Via Investor's Business Daily

Topics Stocks

Glaxo - Vir Biotech's COVID Treatment Approved In Japan ↗

September 27, 2021

Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19...

Via Benzinga

Why Vir Biotechnology Stock Is Sinking This Week ↗

September 24, 2021

Shares fell after an analyst's downgrade.

Via The Motley Fool

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 ↗

September 22, 2021

Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE:

Via Benzinga

Vir Biotechnology Earnings Perspective: Return On Capital Employed ↗

September 06, 2021

According to Benzinga Pro, during Q2, Vir Biotechnology (NASDAQ:VIR) earned $61.02 million, a 138.46% increase from the preceding quarter. Vir Biotechnology also posted a total of...

Via Benzinga

Now May Be the Big Moment for These 2 COVID Stocks ↗

September 02, 2021

Their products are seeing a surge in demand.

Via The Motley Fool

9 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

August 23, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia ↗

August 23, 2021

The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,...

Via Benzinga

3 Vaccine Stocks for the Next Decade ↗

August 09, 2021

Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years?

Via The Motley Fool

Earnings Scheduled For August 5, 2021 ↗

August 05, 2021

Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million. •...

Via Benzinga

European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody ↗

July 28, 2021

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of...

Via Benzinga

Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy ↗

July 15, 2021

Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with...

Via Benzinga

GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know ↗

July 01, 2021

The sample size was small, but the results were impressive.

Via The Motley Fool

EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters ↗

June 29, 2021

The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial...

Via Benzinga

Vir Biotech's HBV Candidates Show Positive Safety Profiles ↗

June 25, 2021

Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

June 25, 2021

Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) stock increased by 39.78% to $3.97 during Friday's regular session. The current volume of 48.4 million shares is 18988....

Via Benzinga

The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs ↗

June 25, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters ↗

June 22, 2021

In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ...

Via Benzinga

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗

June 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients ↗

June 21, 2021

GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

15 Words From Vir Biotechnology's CEO May Mean Market Dominance ↗

June 02, 2021

Vir's antibody treatment is addressing one of the biggest COVID challenges.

Via The Motley Fool

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

All News about Vir Biotechnology, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today